INS and obesity due to melanocortin 4 receptor deficiency: Although most individuals in our study (91%) used glyburide as first-line therapy for GDM, reflecting the policy at the time within our health care system, individuals with indications of greater GDM severity (ie, prepregnancy obesity and higher 50-g OGTT screening values) were more likely to use insulin as first-line therapy.